Device Trial Radar · NCT02148393
Implantation Enhancement by Elective Cryopreservation of All Viable Embryos
Last checked: Nov 19, 2026Latest source record: Mar 9, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
212
Actual
Start
May 2014
Primary completion
Feb 28, 2017
Study completion Feb 28, 2017
Sponsor
- Lead sponsor
- Universitair Ziekenhuis BrusselAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 28, 2014
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years, up to 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A randomised controlled open-label clinical trial to compare the clinical pregnancy rates between fresh embryo transfer and elective all-embryo vitrification with thawing and transfer in a subsequent cycle in high-responders
Conditions
- Infertility
- OHSS
Interventions
Vitrification with subsequent-cycle embryo thawing/transferProcedure
The vitrification process will be performed under the same conditions of all other vitrification procedures usually performed in our centre. In summary, vitrification will be accomplished using closed high security straws (CryoBioSystem®) in combination with dimethylsulfoxide, ethylene glycol and sucrose as cryoprotectants (Irvine ScientificR Freeze Kit®). In the meantime, patients will wait for a subsequent cycle before starting exogenous hormone therapy for endometrial preparation.
Intensified luteal phase support for fresh embryo transferProcedure
A single administration of 1500 IU of exogenous hCG (Pregnyl®) 1 hour after oocyte retrieval followed by daily vaginally-administered progesterone 200 mg tid (Utrogestan®) and oestradiol valerate 2 mg bid (Progynova®).
Pregnyl®Drug
1500 IU
Utrogestan®Drug
200 mg tid
Progynova®Drug
2 mg bid
CryoBioSystem®Device
CryoBioSystem® in combination with dimethylsulfoxide, ethylene glycol and sucrose as cryoprotectants (Irvine ScientificR Freeze Kit®) closed in high security straws
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical pregnancy ratesTime frame: 7 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Universitair Ziekenhuis Brussel
Brussels, Lisboa, Belgium
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.